These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 29168990)
1. Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development. Teng Z; Gupta N; Hua Z; Liu G; Samnotra V; Venkatakrishnan K; Labotka R Clin Transl Sci; 2018 Mar; 11(2):218-225. PubMed ID: 29168990 [TBL] [Abstract][Full Text] [Related]
2. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009 [TBL] [Abstract][Full Text] [Related]
3. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials. Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103 [TBL] [Abstract][Full Text] [Related]
4. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
5. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Kumar S; Durie B; Nahi H; Vij R; Dimopoulos MA; Kastritis E; Terpos E; Leleu X; Beksac M; Goldschmidt H; Hillengass J; Su Z; Hutton B; Cameron C; Khan I; Lam A Leuk Lymphoma; 2019 Jan; 60(1):163-171. PubMed ID: 29741423 [TBL] [Abstract][Full Text] [Related]
6. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712 [TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113 [TBL] [Abstract][Full Text] [Related]
8. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893 [TBL] [Abstract][Full Text] [Related]
9. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768 [TBL] [Abstract][Full Text] [Related]
10. The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines. Ruggeri K; Maguire Á; Cook G JAMA Oncol; 2016 Nov; 2(11):1405-1406. PubMed ID: 27355621 [No Abstract] [Full Text] [Related]
11. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931 [TBL] [Abstract][Full Text] [Related]
12. Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma. Leisch M; Egle A; Greil R Future Oncol; 2019 Jan; 15(2):109-120. PubMed ID: 30111169 [TBL] [Abstract][Full Text] [Related]
13. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Yan X; Xu XS; Weisel KC; Mateos MV; Sonneveld P; Dimopoulos MA; Usmani SZ; Bahlis NJ; Puchalski T; Ukropec J; Bellew K; Ming Q; Sun S; Zhou H Clin Transl Sci; 2020 Nov; 13(6):1345-1354. PubMed ID: 32583948 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961 [TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766 [TBL] [Abstract][Full Text] [Related]
17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson P Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100 [TBL] [Abstract][Full Text] [Related]
18. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H; Hungria V; Spencer A; Palumbo A; Graef T; Eid JE; Houp J; Sun L; Vuocolo S; Anderson KC Lancet Oncol; 2013 Oct; 14(11):1129-1140. PubMed ID: 24055414 [TBL] [Abstract][Full Text] [Related]
19. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472 [TBL] [Abstract][Full Text] [Related]
20. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]